PB0905 - Assessment of therapeutic window for antiplatelet taking cardiology patients: Anysis-P2Y12 assay

Background: Assessment of responsiveness to antiplatelet therapy is vital to preventing thrombotic complications as well as hemorrhagic complications in the management of patients with cardiovascular diseases. However, personalized treatment was not possible in the clinical field because there was no technology that could directly measure the therapeutic window selection of antiplatelet agents.

Aims: This study aims to evaluate the treatment window analysis of the new Anysis-P2Y12 test system.

Methods: In the newly developed platelet function analyzer, Anysis-200, the migration distance (MD) was provided with a cut-off value to determine platelet function status. Here we developed an additional metric, mean velocity, to determine the therapeutic window for antiplatelet dosage.

Results: Depending on the degree of platelet inhibition, the migration distance and average velocity were significantly varied. Since most of the samples with P2Y12 inhibitor extended migration distance exceeding the diagnostic threshold, there was a difficulty in determining the therapeutic window of the drug dosage. However, the introduction of the mean velocity index showed significant differences among the samples according to the degree of platelet inhibition.

Conclusion(s): The present study confirmed that the microfluidic platelet function assay, Anysis-P2Y12 has a new capability to assess the therapeutic window for antiplatelet therapy with high accuracy and precision.